Editorial| Volume 22, ISSUE 1, P7-8, January 2023

Download started.


In the Clear: Long-term pulmonary function benefits associated with Pseudomonas aeruginosa eradication

      Despite significant improvements in life expectancy for individuals with cystic fibrosis (CF) over the last two decades, CF continues to be a life-shortening disorder characterized by progressive, obstructive lung disease associated with chronic airway infection, inflammation, and parenchymal damage. Abnormal ion transport in the CF airways and altered antimicrobial airway defenses result in persistent infections with pathogens such as Pseudomonas aeruginosa. Although the progression of CF lung disease is impacted by many factors, P. aeruginosa infection is clearly associated with irreversible parenchymal damage and a sharper decline in lung function. Earlier age at first infection with P. aeruginosa has been associated with a 2.6 times higher risk of death [
      • Emerson J
      • Rosenfeld M
      • McNamara S
      • Ramsey B
      • Gibson RL.
      Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
      ], and repeated isolation of P. aeruginosa, or colonization, continues to be a major predictor of morbidity and mortality in people with CF.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cystic Fibrosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Emerson J
        • Rosenfeld M
        • McNamara S
        • Ramsey B
        • Gibson RL.
        Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
        Pediatr Pulmonol. 2002; 34: 91-100
      1. Cystic Fibrosis Foundation Patient Registry. 2021 annual data report. Bethesda, Maryland.

        • Döring G
        • Conway SP
        • Heijerman HGM
        • et al.
        Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.
        Eur Respir J. 2000; 16: 749
        • Mogayzel PJ
        • Naureckas ET
        • Robinson KA
        • et al.
        Cystic fibrosis foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial pseudomonas aeruginosa infection.
        Ann Am Thorac Soc. 2014; 11: 1640-1650
        • Littlewood JM
        • Miller MG
        • Ghoneim AT
        • Ramsden CH.
        Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis.
        Lancet Lond Engl. 1985; 1: 865
        • Valerius NH
        • Koch C
        • Høiby N.
        Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment.
        Lancet. 1991; 338: 725-726
        • Mayer-Hamblett N
        • Kronmal RA
        • Gibson RL
        • et al.
        Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
        Pediatr Pulmonol. 2012; 47: 125-134
        • Casaredi IG
        • Shaw M
        • Waters V
        • Seeto R
        • Blanchard AC
        • Ratjen F.
        Impact of antibiotic eradication therapy of Pseudomonas aeruginosa on long term lung function in cystic fibrosis.
        J Cyst Fibros. 2022; (Published online August)S1569199322006452
        • Amin R
        • Lam M
        • Dupuis A
        • Ratjen F.
        The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis.
        Pediatr Pulmonol. 2011; 46: 554-558
        • Rowbotham NJ
        • Smith S
        • Leighton PA
        • et al.
        The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers.
        Thorax. 2018; 73: 388-390

      Linked Article